Veradermics, Incorporated (MANE) — Financial statements
Income statement, balance sheet, and cash flow for Veradermics, Incorporated — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2024 | 2023 | |
|---|---|---|---|
| Revenue & Gross Profit | |||
| Revenue | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | |
| Operating Expenses | |||
| R&D Expenses | 23↑55.5% | 15 | |
| General & Administrative Expenses | 3↑48.5% | 2 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | |
| SG&A Expenses | 3↑48.5% | 2 | |
| Other Expenses | 0.00 | 0.00 | |
| Operating Expenses | 27↑54.6% | 17 | |
| Total Costs & Expenses | 27↑54.6% | 17 | |
| Operating Results | |||
| Operating Income | -27↓54.6% | -17 | |
| Depreciation & Amortization | 0.00 | 0.00 | |
| EBITDA | -26↓57.4% | -16 | |
| EBIT | -26↓57.4% | -16 | |
| Interest & Other Income | |||
| Net Interest Income | -0.10↓112.5% | 0.83 | |
| Interest Income | 0.48↓44.7% | 0.87 | |
| Interest Expense | 0.59↑1525.0% | 0.04 | |
| Non-Operating Income | -0.88↓0.6% | -0.87 | |
| Other Income / Expenses | 0.29↓65.2% | 0.83 | |
| Income Before Tax | -26↓60.6% | -16 | |
| Income Tax Expense | 0.00 | 0.00 | |
| Net Income & EPS | |||
| Net Income from Continuing Operations | -26↓60.6% | -16 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | |
| Net Income | -26↓60.6% | -16 | |
| Bottom-Line Net Income | -27↓65.6% | -16 | |
| EPS (Basic) | -0.14↓70.9% | -0.08 | |
| EPS (Diluted) | -0.14↓70.9% | -0.08 | |
| Weighted Average Shares | 201↑0.0% | 201 | |
| Weighted Average Diluted Shares | 201↑0.0% | 201 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.